Marker Therapeutics (FRA:GX1) Treasury Stock: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GX1 Marker Therapeutics Inc FRA:GX1
32 GF Score
Price €0.96
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Treasury Stock?

Marker Therapeutics FRA:GX1 +13.69% 32 Treasury Stock is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:GX1 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Marker Therapeutics's treasury stock for the quarter that ended in Jun. 2026 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Marker Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Treasury Stock Chart

Marker Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marker Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:GX1
32GF Score
Marker Therapeutics Inc FRA:GX1
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €0.00 Mil mean?
Marker Therapeutics (FRA:GX1) has a Treasury Stock of €0.00 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Marker Therapeutics and its competitors.
Is Marker Therapeutics' Treasury Stock too high?
Marker Therapeutics' current Treasury Stock is €0.00 Mil. Overall, Marker Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Treasury Stock compare to NCEL and HOWL?
Marker Therapeutics' Treasury Stock of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Marker Therapeutics and its competitors. Marker Therapeutics's current Treasury Stock is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current Treasury Stock of €0.00 Mil. The current Treasury Stock is €0.00 Mil. Marker Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current Treasury Stock is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges MRKR:USA
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
32GF Score

Get the complete analysis for FRA:GX1

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price